FTC slams pharmacy benefit managers in first report from ongoing investigation

On Tuesday, regulators updated the public on their almost three-year-old inquiry into PBMs’ anticompetitive business practices. The report is not positive for the drug middlemen, which immediately criticized it as one-sided.